Abstract
The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
Keywords: Anticancer drugs, mass spectrometry, ovarian cancer, paclitaxel, proteomics, two-dimensional electrophoresis
Current Cancer Drug Targets
Title:The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors
Volume: 12 Issue: 8
Author(s): D. Vergara, A. Tinelli, A. Iannone and M. Maffia
Affiliation:
Keywords: Anticancer drugs, mass spectrometry, ovarian cancer, paclitaxel, proteomics, two-dimensional electrophoresis
Abstract: The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival. Although most patients respond to this first-line therapy, initially, the majority of these patients relapse within 2 years. The mechanisms responsible for acquired drug resistance in ovarian cancer have been elucidated only in part. They include i) enhanced drug export, ii) activation/inhibition of intracellular signalling pathways, iii) molecular alterations in tubulin isotype composition. A better understanding of these mechanisms is needed, in order to develop new approaches, aimed at overcoming resistance to anticancer agents, and to reveal the complexity of causes, which contribute to drug resistance. In this review we offer an updated overview of proteomic studies on the molecular mechanisms of paclitaxel resistance. These proteomic studies also identify potential targets for modulating drug resistance, that could be predictive of response to chemotherapy in ovarian carcinomas.
Export Options
About this article
Cite this article as:
Vergara D., Tinelli A., Iannone A. and Maffia M., The Impact of Proteomics in the Understanding of the Molecular Basis of Paclitaxel-Resistance in Ovarian Tumors, Current Cancer Drug Targets 2012; 12 (8) . https://dx.doi.org/10.2174/156800912803251171
DOI https://dx.doi.org/10.2174/156800912803251171 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Metal-organic Nanopharmaceuticals
Pharmaceutical Nanotechnology Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery 3dswap-pred: Prediction of 3D Domain Swapping from Protein Sequence Using Random Forest Approach
Protein & Peptide Letters Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Current Research on Opioid Receptor Function
Current Drug Targets <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Perspectives of New Therapies for Endometriosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry Translational Theragnosis of Ovarian Cancer: where do we stand?
Current Medicinal Chemistry